Arca
Skip to content
Tools
Tools

CXCR4: C-X-C chemokine receptor type 4

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation.

  • Drugs that act on it: 8
  • Approved: 2
  • In phases 1 to 3: 6
  • Sponsors: 7

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CXCR4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody
  • Protein or peptide

Approved2

  • Plerixafor
  • Mavorixafor

Phase 32

  • Motixafortide
  • Balixafortide

Phase 23

  • Burixafor
  • CTCE-9908
  • Ulocuplumab

Phase 11

  • MSX-122

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • GPCR Therapeutics, Inc.113%
  • Metastatix, Inc.113%
  • Polyphor Ltd.113%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule450%
  • Antibody113%
  • Protein or peptide338%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 6 of 8 act as: C-X-C chemokine receptor type 4 antagonist; the rest name their own mechanism.
PlerixaforApprovedSanofiSmall moleculePartial agonistC-X-C chemokine receptor type 4 partial agonist29—
MavorixaforApprovedX4 PharmaceuticalsSmall moleculeAntagonist—2—
MotixafortidePhase 3Ayrmid PharmaProtein or peptideAntagonist—6—
BalixafortidePhase 3Polyphor Ltd.Protein or peptideAntagonist—2—
BurixaforPhase 2GPCR Therapeutics, Inc.Small moleculeAntagonist—0—
CTCE-9908Phase 2—Protein or peptideAntagonist—0—
UlocuplumabPhase 2Bristol-Myers SquibbAntibodyInhibitorC-X-C chemokine receptor type 4 inhibitor0—
MSX-122Phase 1Metastatix, Inc.Small moleculeAntagonist—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.
A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersMavorixaforPhase 2Not yet recruitingX4 Pharmaceuticals2026-10-29
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMPlerixaforPhase 1 / Phase 2Enrolling by invitationNational Institute of Allergy and Infectious Diseases (NIAID)2026-08-20
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialPlerixaforPhase 2RecruitingNational Cancer Institute (NCI)2026-05-26
Stem Cell Mobilization and Apheresis for Life-threatening Blood DisordersPlerixaforPhase 1RecruitingSt. Jude Children's Research Hospital2026-05-13
Motixafortide for MRD Sensitization in AMLMotixafortidePhase 2RecruitingWashington University School of Medicine2026-02-06
STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASEPlerixaforPhase 1 / Phase 2Not yet recruitingHospital Israelita Albert Einstein2026-01-14
Mozobil for Autologous Hematopoietic Stem Cell TransplantationPlerixaforPhase 2RecruitingThomas Jefferson University2025-09-23
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)Plerixafor—RecruitingNorthwell Health2025-09-22
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE TrialMotixafortidePhase 4RecruitingEmory University2025-08-03
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal AdenocarcinomaBalixafortidePhase 1Not yet recruitingArsen Osipov2025-05-21
Allo HSCT for High Risk HemoglobinopathiesPlerixaforPhase 2RecruitingMasonic Cancer Center, University of Minnesota2025-03-12
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyPlerixaforPhase 1 / Phase 2Enrolling by invitationNational Institute of Allergy and Infectious Diseases (NIAID)2025-02-28
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic StatusBalixafortide—RecruitingYunnan Cancer Hospital2024-12-03
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsMotixafortidePhase 3RecruitingGuangzhou Gloria Biosciences Co., Ltd.2024-07-23
Gene Editing For Sickle Cell DiseaseMotixafortidePhase 1RecruitingSt. Jude Children's Research Hospital2024-07-17
SCD Stem Cell Mobilization and Apheresis Using MotixafortideMotixafortidePhase 1RecruitingSt. Jude Children's Research Hospital2024-06-04
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsMavorixaforPhase 3RecruitingX4 Pharmaceuticals2023-09-28
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaMotixafortidePhase 2Active, not recruitingColumbia University2020-09-09

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
WHIM syndrome
0.80
WHIM syndrome 1
0.74
Plasma cell myeloma
0.66
HIV infectious disease
0.58
Neoplasm
0.54
Severe congenital neutropenia
0.46
Skin neoplasm
0.40
B-cell non-Hodgkin lymphoma
0.38
Lymphoid neoplasm
0.38

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2107, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P61073, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.